NKTR Nektar Therapeutics
NKTR Nektar Therapeutics
Healthcare · Biotechnology
Market read
Scan convergence 2 scans as of 2026-08-17 2 neutral converging
POC $60.34 · VWAP $61.30 · +18.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
3 watchlists
NKTR Price Structure
Loading timeframes…
Peers
Every watchlist NKTR belongs to, members best 30-day change first — NKTR highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
@monster-discoveries
Reported the quarter ending 2026-03-31: revenue $11M, diluted EPS $-1.82, net income $-45M (SEC filing). Across the print the stock moved -3.8% (close before → first close after).
full note →Against street estimates
How NKTR's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about NKTR from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Nektar Therapeutics (NKTR) Stock Price & Overview
- Deadline Soon: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
- Nektar Therapeutics Proxy statement: Proxy filing
- Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
NKTR research tape
33 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.